Home > Product > APIs > Atosiban


(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin; Antocin; Tractocile; RWJ 22164; RWJ22164; RWJ-22164; ORF 22164; ORF22164; ORF-22164; deTVT; dE-TVT; Atosibanum ; Atosiban; d(TVT); CAP 476
3-Mercaptopropionyl-D-Tyr(Et)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2 (Disulfide bond)
Molecular Formula
Atosiban is an oxytocin and vasopressin antagonist. It is used as a tocolytic in the management of preterm labor.
Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban is indicated to delay imminent pre-term birth in pregnant adult women. Atosiban is useful in improving the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in patients with repeated implantation failure (RIF). The pregnancy rate improved from zero to 43.7%.
Areas of Interest
Hormonal therapy
  • Background
  • Related Products
  • References

The oxytocin antagonist atosiban was found to be better tolerated by both mother and fetus than salbutamol, with a comparable neonatal and infant safety profile, and atosiban was as effective as salbutamol in delaying threatened preterm birth. This study supports the clinical use of atosiban in the treatment of preterm labor.

CAS: 57982-77-1 (net)
Sequence: Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt acetate salt
M.W: 1239.43
Molecular Formula: C60H86N16O13
CAS: 57773-65-6 (net)
Sequence: Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt acetate salt
M.W: 1281.64
Molecular Formula: C64H83N17O12
CAS: 16679-58-6
Sequence: 3-Mercaptopropionyl-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 acetate salt (Disulfide bond)
M.W: 1069.2
Molecular Formula: C46H64N14O12S2
CAS: 38234-21-8 (net)
Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-NHEt acetate salt
M.W: 1153.31
Molecular Formula: C55H76N16O12
CAS: 123246-29-7
Sequence: Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2
M.W: 1570.4
Molecular Formula: C80H113ClN18O13

In this trial the treatment of patients in preterm labor with atosiban resulted in prolongation of pregnancy for up to 7 days for those at a gestational age > or =28 weeks, and this occurred with a low rate of maternal-fetal adverse effects. In addition, at a gestational age > or =28 weeks, the infant morbidity and mortality of atosiban-initiated standard care were similar to those with placebo-initiated standard care.

Romero R, Sibai B M, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue[J]. American journal of obstetrics and gynecology, 2000, 182(5): 1173-1183.

Atosiban is an effective and safe drug for the acute treatment of preterm labor with minimal side effects, and it can be an option in the treatment of preterm labor, especially in patients with heart disease and multi-fetal pregnancies.

Kashanian M, Akbarian A R, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor[J]. International Journal of Gynecology & Obstetrics, 2005, 91(1): 10-14.

Maintenance therapy with the oxytocin receptor antagonist atosiban can prolong uterine quiescence after successful treatment of an acute episode of preterm labor with atosiban. Treatment was well tolerated.

Valenzuela G J, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban[J]. American journal of obstetrics and gynecology, 2000, 182(5): 1184-1190.

Online Inquiry

Name (First Last) *
Email *
Phone *
Service & Products of Interest *
Services Required and Project Description
Verification code *Please enter the code "peptides"
Home | Site Map | Contact Us | Resources
Copyright © 2008 - Creative Peptides. All rights reserved.